RB1 and small cell lung carcinoma: Despite the rarity of MAPK pathway mutations in SCLC, two clinical samples (P-0039208-T01-IM6 and P-0039208-T02-IM6) carried KRAS amplifications without TP53 and RB1 mutations23.